Open Access

Bronchioloalveolar invasion in non-small cell lung cancer is associated with expression of transforming growth factor-β1

  • Kazuhiro Imai1Email author,
  • Yoshihiro Minamiya1,
  • Akiteru Goto2,
  • Hiroshi Nanjo2,
  • Hajime Saito1,
  • Satoru Motoyama1,
  • Yusuke Sato1,
  • Satoshi Kudo1,
  • Shinogu Takashima1,
  • Yasushi Kawaharada1,
  • Nobuyasu Kurihara1,
  • Kimito Orino1 and
  • Jun-ichi Ogawa1
World Journal of Surgical Oncology201311:113

https://doi.org/10.1186/1477-7819-11-113

Received: 22 November 2012

Accepted: 13 May 2013

Published: 25 May 2013

Abstract

Background

Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) with fibrous stromal invasion are newly introduced subtypes of small lung adenocarcinoma. AIS is a small localized adenocarcinoma in which growth is restricted to neoplastic cells along preexisting alveolar structures without fibrous stromal invasion. In MIA, by contrast, tumor cells have infiltrated the myofibroblastic stroma. Transforming growth factor (TGF)-β is known to be produced by progressor tumors, and excessive TGF-β contributes to a pathological excess of tissue fibrosis. TGF-β1 is the most abundant isoform, and its expression is a key event fostering tumor invasion and metastasis. We therefore analyzed the relationship between TGF-β1 expression and clinicopathological microinvasion in patients with small lung adenocarcinoma.

Methods

The study participants were 45 patients who underwent curative surgery for AIS and MIA 3 cm or less in size. Those tumors were assessed based on immunohistochemical staining using anti-TGF-β1 antibody. The TGF-β1 status was assessed immunohistochemically using the Allred 8-unit system.

Results

The rates of TGF-β1 positivity in the AIS and MIA groups were 27.3% and 65.2%, respectively (P <0.05). The median of Allred score was 0.5 (range 0–5) in the AIS group and 3.0 (range 0–6) in the MIA group (P = 0.0017).

Conclusions

We suggest that TGF-β1 expression is likely to be significantly stronger in patients with MIA than in those with AIS, and the increased expression may be associated with minimal invasion and infiltration of the myofibroblastic stroma.

Keywords

Adenocarcinoma in situLung cancerMinimally invasive adenocarcinomaTransforming growth factor-β1

Background

Adenocarcinoma is the most common histological type among lung cancers. As with malignancies in other organs such as the breast and cervix, where carcinomas are defined as non-invasive, micro-invasive or invasive, the extent of the invasive component in lung adenocarcinomas is associated with clinical outcomes [1]. To address advances in oncology, molecular biology, pathology, radiology, and surgery, an international multidisciplinary classification was sponsored by the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society, and the European Respiratory Society [2]. Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) with fibrous stromal invasion are newly introduced subtypes, while the older term of bronchioloalveolar carcinoma does no longer exist according to new IASLC classification of lung adenocarcinoma. AIS is a localized small (≤3 cm) adenocarcinoma, the growth of which is restricted to neoplastic cells along preexisting alveolar structures without stromal, vascular or pleural invasion. Papillary or micropapillary patterns and intra-alveolar tumor cells are absent. MIA is a small, solitary adenocarcinoma growing in a predominantly lepidic pattern and showing ≤5 mm invasion in its greatest dimension at any one focus. If these tumors are completely resected, there will be 100% or near 100% disease-specific survival.

Transforming growth factor (TGF)-β reportedly promotes cancer metastasis by affecting the tumor microenvironment in a manner that facilitates tumor cell invasion [3, 4]. Several tumors, including those arising in the lung [57], express high levels of TGF-β, which correlate with tumor progression and clinical prognosis. Humans express three highly homologous isoforms of TGF-β (TGF-βs 1, 2, and 3), which share 70% sequence identity in their biologically active C-terminal regions, and all of which bind to the same receptor complex and activate the same downstream signaling pathways. TGF-β1 is the most abundant and most extensively studied isoform [8].

We previously showed that tumor-derived TGF-β1 causes a reduction in the number of dendritic cells within the sentinel lymph node in lung cancer [9]. Our findings also suggest that TGF-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung [10]. In addition, we showed that overexpression of TGF-β1 by tumor cells promotes metastasis into tumor-draining lymph nodes in mice, most likely by inhibiting dendritic cell migration from tumors towards tumor-draining nodes [11]. Collectively, these results suggest that TGF-β1 is a key mediator fostering tumor invasion and metastasis. We therefore analyzed the relationship between TGF-β1 expression and clinicopathological microinvasion in patients with small lung adenocarcinoma.

Methods

Patients

In total, 453 patients who had undergone major pulmonary resections for non-small cell lung cancer (NSCLC) were enrolled in the study. Among them, 45 patients (10.1%) with NSCLC had AIS and MIA subtypes of small lung adenocarcinoma 3 cm or less in size. All had undergone surgery in the Department of Chest, Breast and Endocrine Surgery, University Hospital of Akita University Graduate School of Medicine, between January 2004 and December 2011. This study was approved by our institutional review boards, and written informed consent was obtained from all patients. The patients’ characteristics are listed in Table 1. The 7th edition of the TNM staging system was used for evaluation [12].
Table 1

Clinical details of all patients who underwent pulmonary resection for small lung adenocarcinoma

 

AIS

MIA

P value

n

22

23

 

Age (year)

63±11.9

67±9.3

0.232

Gender (M/F)

8/14

8/15

0.675

Tumor size

11.1±3.7

15.0±5.6

0.022*

Nodal involvement

  

0.162

 N0

22

22

 

 N1

0

1

 

 N2

0

0

 

Stage

  

0.243

 IA

22

22

 

 IB

0

0

 

 IIA

0

1

 

AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, *P <0.05.

Pathology

Surgically resected specimens were fixed in 10% formalin and routinely processed for paraffin embedding. Histological sections were cut into 4-mm slices, which were then stained with hematoxylin and eosin (HE) and elastica Masson using standard methods, and were reviewed by two pathologists (A.G. and H.N.). Experienced pathologists diagnosed the subtypes of the primary tumors according to IASLC/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of adenocarcinoma [2]. Diagnosis of AIS or MIA was based on the HE staining (Figure 1).
Figure 1

International multidisciplinary classification of lung adenocarcinoma. (a) Adenocarcinoma in situ. Histologic specimen showing a tumor with atypical pneumocytes proliferating along slightly thickened but preserved alveolar walls; (b) Minimally invasive adenocarcinoma. Histologic specimen of a tumor exhibiting a bronchioloalveolar growth pattern with minimal invasion. The tumor is invading in the fibrous stroma.

Immunohistochemistry of TGF-β1 in small lung adenocarcinoma

After reviewing HE-stained sections of the tumor specimens, we selected blocks from the central regions of the tumors for further study. The paraffin-embedded tumor tissues were cut into 4-μm-thick sections and deparaffinized. Small lung adenocarcinomas were then assessed based on standard immunohistochemical (IHC) staining using goat polyclonal anti-TGF-β1 (1:50 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-goat horseradish peroxidase (1:100 dilution), and diaminobenzidene stain (Figure 2). The TGF-β1 staining was scored using the Allred 8-unit system with the combination of a proportion score from 0 to 5 and an intensity score from 0 to 3. The proportion score included the fraction of positively stained tumor cells and was as follows: 0 = none, 1 ≤1/100; 2 = 1/100 to 1/10; 3 = 1/10 to 1/3; 4 = 1/3 to 2/3; 5 ≥2/3. The staining intensity score was as follows: 0 = none; 1 = weak; 2 = intermediate; 3 = strong [13, 14].
Figure 2

Immunostaining adenocarcinoma in situ and minimally invasive adenocarcinoma using an anti-TGF-β1 antibody. (a) TGF-β1-positive MIA sample. TGF-β1-positive cells are stained brown. TGF-β1-positive cells are predominantly observed in the tumor itself. This sample has an Allred score of 6/8; (b) TGF-β1-negative AIS sample. This sample has an Allred score of 0/8. TGF: Transforming growth factor; AIS: Adenocarcinoma in situ; MIA: Minimally invasive adenocarcinoma.

Immunohistochemical detection of micrometastasis and isolated tumor cells in dissected lymph nodes

Isolated tumor cells and lymph node micrometastasis were assessed in all patients based on HE staining and IHC using AE1/AE3 antibodies. One section of the maximum cut surface of each lymph node was immunohistochemically labeled with AE1/AE3 monoclonal mouse anti-human cytokeratin clones using an EnVision system (DAKO Corporation, Carpinteria, CA, USA), which was used to detect the presence of micrometastases and isolated tumor cells. A result was considered positive if positive cell clusters or individual cells with the appropriate tumor cell morphology were recognized. As proposed by the 7th edition of the TNM staging system [12], isolated tumor cells were not considered as positive, but were defined as pN0(i+) in this study.

Statistics

Group data were expressed as means ± SD. Categorical data were compared using the χ2 test. The significance of individual differences was evaluated using the Wilcoxon test. Values of P <0.05 were considered to be significant. JMP IN 8.0.2 software (SAS Institute, Cary, NC, USA) was used for all statistical evaluations.

Results

There were no differences between the AIS and MIA groups with respect to age, gender, nodal involvement or pathological stage; however, tumor size was greater in the MIA group than the AIS group (Table 1). Table 2 shows the incidence of TGF-β1 expression detected upon immunohistochemical examination in the AIS and MIA groups. Figure 3 shows the differences in TGF-β1 immunostaining between AIS and MIA scored using the Allred method. The rate of TGF-β1 positivity was significantly (P <0.05) higher in the MIA group (65.2%; 15/23) than the AIS group (27.3%; 6/22). Similarly, the median Allred score for TGF-β1 expression was significantly higher (P = 0.0017) in the MIA group than the AIS group (3.0 (range 0–6) vs. 0.5 (range 0–5)).
Table 2

Incidence of TGF-β1 expression in the AIS and MIA groups

 

TGF-β1 expression positive stain (%)

AIS (n=22)

27.3

MIA (n=23)

65.2*

AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, *P <0.05.

Figure 3

Allred score system devised to score results from immunohistochemical tests of TGF-β1. Differences in TGF-β1 immunostaining between AIS and MIA scored using the Allred method; *P <0.05.

One instance of lymph node metastasis was detected in the MIA group using HE and IHC staining with AE1/AE3 antibodies. In addition, isolated tumor cells were found in a second patient diagnosed with MIA (Figure 4). This patient was staged as pT1aN0(i+)M0. The overall survival rates differed somewhat between AIS and MIA patients (100% vs. 89.5%), but that difference did not reach statistical significance (P = 0.093).
Figure 4

Isolated tumor cells in a dissected lymph node. Isolated tumor cells were detected by immunostaining using anti-cytokeratin antibody in a patient diagnosed with MIA. The patient’s pathological stage was pT1aN(i+)M0, Stage IA.

Discussion

The results of the present study suggest that patients with MIA show greater expression of TGF-β1 than patients with AIS, as indicated by the significantly greater TGF-β1 positivity rate and Allred score. In addition, HE and IHC staining revealed that lymph node metastasis and isolated tumor cells were only present in the MIA group. Thus, TGF-β1 expression by adenocarcinomas appears to be an important factor associated with clinicopathological microinvasion in patients with small lung adenocarcinoma.

TGF-β increases the invasiveness of cancer cells by increasing their proteolytic activity and promoting their binding to cell-adhesion molecules [15]. In an earlier study, we demonstrated that tumor-derived TGF-β1 induces dendritic cell apoptosis within lymph nodes in non-small cell lung cancer [9], and that overexpression of TGF-β1 by tumor cells promotes lymph node metastasis in mice [11]. Consistent with those findings, the effects of TGF-β1 on angiogenesis, stroma formation and immune function appear to further support tumor progression and invasion [16, 17]. AIS is a small localized adenocarcinoma in which growth is restricted to neoplastic cells along preexisting alveolar structures without fibrous stromal invasion. In MIA, by contrast, tumor cells have infiltrated the myofibroblastic stroma. In many diseases, excessive TGF-β contributes to a pathological excess of tissue fibrosis that compromises normal organ function, a topic that has been the subject of several reviews [1820]. However, we provide no direct evidence of the mechanism by which TGF-β1 increases tissue fibrosis in MIAs.

The Noguchi classification [21] is predictive of outcome in patients with small adenocarcinomas, with type D, E, and F tumors showing a worse outcome than the other tumor types. However, the majority of small adenocarcinomas are classified as type C, so that subclassification of type C tumors does seem necessary. Tumors that meet the criteria for AIS were formerly classified as bronchioloalveolar carcinoma based on the strict definition of type A and type B adenocarcinomas from the 1995 Noguchi classification [21]. MIAs are tumors showing lepidic growth and a small (≤5 mm) area of invasion. The MIA invades areas of stromal fibrosis in an acinar pattern. Nearly all type C adenocarcinomas can be classified as MIAs. The outcome of patients with adenocarcinomas with diameters of 2 cm or less can be predicted using the following scoring system based on three histological criteria: 1) the tumor is lymphovascular invasion-positive; 2) the non-bronchioloalveolar carcinoma component is >10 mm in diameter; and 3) the percentage of the solid, cribriform, and/or papillary components is ≥30% of the entire tumor volume [22]. Patients whose MIAs have a non-bronchioloalveolar carcinoma component ≤5 mm show 100% survival [22, 23]. Consistent with that finding, no difference in survival was observed between AIS and MIA in the present study. However, nodal involvement was observed in 2 of 23 patients with MIA. We therefore suggest that it would be problematic to conduct limited surgery for MIA patients with micrometastasis or isolated tumor cells, though some MIAs may be candidates for limited surgery.

Conclusions

In conclusion, our findings suggest that patients with MIAs have both a significantly greater rate of TGF-β1 positivity and higher TGF-β1 Allred scores than patients with AIS. However, because we do not provide direct evidence of the mechanism by which TGF-β1 increases tissue fibrosis in MIAs, and we examined only a limited number of patients, further studies will be needed to more precisely define the role played by tumor-derived TGF-β1 in determining the invasiveness of adenocarcinoma of the lung.

Abbreviations

AIS: 

Adenocarcinoma in situ

HE: 

hematoxylin and eosin

IHC: 

immunohistochemical

MIA: 

Minimally invasive adenocarcinoma

NSCLC: 

Non-small cell lung cancer

TGF: 

Transforming growth factor.

Declarations

Authors’ Affiliations

(1)
Department of Chest, Breast and Endocrine Surgery, Akita University Graduate School of Medicine
(2)
Department of Pathology, Akita University Graduate School of Medicine

References

  1. Toonkel RL, Borczuk AC, Powell CA: TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol. 2010, 5: 153-157. 10.1097/JTO.0b013e3181c8cc0c.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011, 6: 244-285. 10.1097/JTO.0b013e318206a221.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Giampieri S, Pinner S, Sahai E: Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res. 2010, 70: 3435-3439. 10.1158/0008-5472.CAN-10-0466.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Korpal M, Kang Y: Targeting the transforming growth factor-beta signaling pathway in metastatic cancer. Eur J Cancer. 2010, 46: 1232-1240. 10.1016/j.ejca.2010.02.040.View ArticlePubMedGoogle Scholar
  5. Barthelemy-Brichant N, David JL, Bosquée L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet-Mahieu L, Deneufbourg JM: Increased TGF beta1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest. 2002, 32: 193-198. 10.1046/j.1365-2362.2002.00956.x.View ArticlePubMedGoogle Scholar
  6. Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004, 172: 7335-7340.View ArticlePubMedGoogle Scholar
  7. Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R: Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp (Warsz). 2006, 54: 143-147. 10.1007/s00005-006-0016-0.View ArticleGoogle Scholar
  8. Flanders KC, Wakefield LM: Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia. 2009, 14: 131-144. 10.1007/s10911-009-9122-z.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, Imai K, Hirokawa M, Ogawa J: Tumor-derived TGF beta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol. 2006, 176: 5637-5643.View ArticlePubMedGoogle Scholar
  10. Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, Toda H, Motoyama S, Ogawa J: Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol. 2010, 31: 437-441. 10.1007/s13277-010-0052-6.View ArticlePubMedGoogle Scholar
  11. Imai K, Minamiya Y, Koyota S, Ito M, Saito H, Sato Y, Motoyama S, Sugiyama T, Ogawa J: Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res. 2012, 31: 3-10.1186/1756-9966-31-3.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Sobin LH, Gospodarowicz MK, Wittekind C: (Eds): TNM Classification of Malignant Tumours. 2009, New York: Wiley-Blackwell, 7Google Scholar
  13. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMedGoogle Scholar
  14. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004, 10: 184-190. 10.1158/1078-0432.CCR-1405-2.View ArticlePubMedGoogle Scholar
  15. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K: Role of transforming growth factor-b 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol. 1999, 17: 607-614.PubMedGoogle Scholar
  16. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K: Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001, 91: 964-971. 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
  17. Weeks BH, He W, Olson KL, Wang XJ: Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res. 2001, 61: 7435-7443.PubMedGoogle Scholar
  18. Bonewald LF: Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr. 1999, 9: 33-44.PubMedGoogle Scholar
  19. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994, 331: 1286-1292. 10.1056/NEJM199411103311907.View ArticlePubMedGoogle Scholar
  20. Moses HL, Yang EY, Pietenpol JA: TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990, 63: 245-247. 10.1016/0092-8674(90)90155-8.View ArticlePubMedGoogle Scholar
  21. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, Shimosato Y: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995, 75: 2844-2852. 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
  22. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H: Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol. 2010, 5: 333-339. 10.1097/JTO.0b013e3181c8cb95.View ArticlePubMedGoogle Scholar
  23. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Maeshima AM, Matsuno Y, Asamura H: Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004, 28: 198-206. 10.1097/00000478-200402000-00007.View ArticlePubMedGoogle Scholar

Copyright

© Imai et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement